Literature DB >> 19217025

Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride.

Rajesh Narendran1, W Gordon Frankle, N Scott Mason, Eugenii A Rabiner, Roger N Gunn, Graham E Searle, Shivangi Vora, Maralee Litschge, Steve Kendro, Thomas B Cooper, Chester A Mathis, Marc Laruelle.   

Abstract

The use of PET and SPECT endogenous competition binding techniques has contributed to the understanding of the role of dopamine in several neuropsychiatric disorders. An important limitation of these imaging studies is the fact that measurements of acute changes in synaptic dopamine have been restricted to the striatum. The ligands previously used, such as [(11)C]raclopride and [(123)I]IBZM, do not provide sufficient signal to noise ratio to quantify D(2) receptors in extrastriatal areas, such as cortex, where the concentration of D(2) receptors is much lower than in the striatum. Given the importance of cortical DA function in cognition, a method to measure cortical dopamine function in humans would be highly desirable. The goal of this study was to compare the ability of two high affinity DA D(2) radioligands [(11)C]FLB 457 and [(11)C]fallypride to measure amphetamine-induced changes in DA transmission in the human cortex. D(2) receptor availability was measured in the cortical regions of interest with PET in 12 healthy volunteers under control and postamphetamine conditions (0.5 mg kg(-1), oral), using both [(11)C]FLB 457 and [(11)C]fallypride (four scans per subjects). Kinetic modeling with an arterial input function was used to derive the binding potential (BP(ND)) in eight cortical regions. Under controlled conditions, [(11)C]FLB 457 BP(ND) was 30-70% higher compared with [(11)C]fallypride BP(ND) in cortical regions. Amphetamine induced DA release led to a significant decrease in [(11)C]FLB 457 BP(ND) in five out the eight cortical regions evaluated. In contrast, no significant decrease in [(11)C]fallypride BP(ND) was detected in cortex following amphetamine. The difference between [(11)C]FLB 457 and [(11)C]fallypride ability to detect changes in the cortical D(2) receptor availability following amphetamine is related to the higher signal to noise ratio provided by [(11)C]FLB 457. These findings suggest that [(11)C]FLB 457 is superior to [(11)C]fallypride for measurement of changes in cortical synaptic dopamine. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19217025     DOI: 10.1002/syn.20628

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  63 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

2.  Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study.

Authors:  Robert H Mach; Zhude Tu; Jinbin Xu; Shihong Li; Lynne A Jones; Michelle Taylor; Robert R Luedtke; Colin P Derdeyn; Joel S Perlmutter; Mark A Mintun
Journal:  Synapse       Date:  2011-03-21       Impact factor: 2.562

3.  Positron emission tomography imaging of dopamine D₂/₃ receptors in the human cortex with [¹¹C]FLB 457: reproducibility studies.

Authors:  Rajesh Narendran; N Scott Mason; Maureen A May; Chi-Min Chen; Steve Kendro; Khanum Ridler; Eugenii A Rabiner; Marc Laruelle; Chester A Mathis; W Gordon Frankle
Journal:  Synapse       Date:  2011-01       Impact factor: 2.562

4.  Nociceptin Receptors in Alcohol Use Disorders: A Positron Emission Tomography Study Using [11C]NOP-1A.

Authors:  Rajesh Narendran; Roberto Ciccocioppo; Brian Lopresti; Jennifer Paris; Michael L Himes; N Scott Mason
Journal:  Biol Psychiatry       Date:  2017-05-31       Impact factor: 13.382

5.  [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.

Authors:  Jinbin Xu; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2009-09       Impact factor: 2.562

6.  Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum.

Authors:  Christin Schifani; Sina Hafizi; Huai-Hsuan Tseng; Cory Gerritsen; Miran Kenk; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi
Journal:  Schizophr Res       Date:  2018-11-06       Impact factor: 4.939

7.  Cocaine cue-induced dopamine release in the human prefrontal cortex.

Authors:  Michele S Milella; Aryandokht Fotros; Paul Gravel; Kevin F Casey; Kevin Larcher; Jeroen A J Verhaeghe; Sylvia M L Cox; Andrew J Reader; Alain Dagher; Chawki Benkelfat; Marco Leyton
Journal:  J Psychiatry Neurosci       Date:  2016-08       Impact factor: 6.186

8.  Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride.

Authors:  Mark Slifstein; Lawrence S Kegeles; Xiaoyan Xu; Judy L Thompson; Nina Urban; John Castrillon; Elizabeth Hackett; S-A Bae; Marc Laruelle; Anissa Abi-Dargham
Journal:  Synapse       Date:  2010-05       Impact factor: 2.562

Review 9.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

10.  Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers.

Authors:  Ningning Guo; Wen Guo; Michaela Kralikova; Man Jiang; Ira Schieren; Raj Narendran; Mark Slifstein; Anissa Abi-Dargham; Marc Laruelle; Jonathan A Javitch; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.